Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials. It is specifically engineered to target death-receptor 5 for the management of advanced, unresectable, or metastatic conventional chondrosarcoma. INBRX-106, a hexavalent sdAb-based investigational treatment targeting OX4, is also in Phase 2 clinical development. This candidate is being evaluated for its potential to treat a diverse array of metastatic solid tumors, encompassing non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancers, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Established in 2024, Inhibrx Biosciences maintains its headquarters in La Jolla, California.